BGAI
BMRN icon

Bruce G. Allen Investments’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bruce G. Allen Investments’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35
Closed -$2.47K – 1091
2025
Q1 		$2.47K Buy
35
+21
+150% +$1.41K ﹤0.01% 671
2024
Q4 		$920 Sell
14
-16
-53% -$1.07K ﹤0.01% 842
2024
Q3 		$2.11K Sell
30
-9
-23% -$752 ﹤0.01% 701
2024
Q2 		$3.21K Buy
39
+23
+144% +$1.92K ﹤0.01% 624
2024
Q1 		$1.4K Hold
16
– – ﹤0.01% 741
2023
Q4 		$1.54K Buy
+16
New +$1.42K ﹤0.01% 783

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bruce G. Allen Investments's BMRN Position: Q2 2025 in Review

Bruce G. Allen Investments sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 35 shares — an estimated $2.47K sold.

Bruce G. Allen Investments first reported a position in BMRN in Q4 2023 and held it in 6 quarters. The position peaked at $3.21K in Q2 2024. 582 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Bruce G. Allen Investments reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Bruce G. Allen Investments sold 35 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $2.47K.
  • Bruce G. Allen Investments first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 6 quarters.
  • Bruce G. Allen Investments's BioMarin Pharmaceuticals position peaked at $3.21K in Q2 2024.
  • 582 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Bruce G. Allen Investments's 13F filing for Q2 2025, filed 9 Jul 2025.